Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,138 | 2 | 84.5% |
| Food and Beverage | $393.19 | 6 | 15.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,210 | 4 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $165.23 | 2 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $133.44 | 1 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $21.81 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $160.18 | 2 | E.R. Squibb & Sons, L.L.C. ($133.44) |
| 2022 | $337.50 | 1 | ABBVIE INC. ($337.50) |
| 2021 | $1,868 | 3 | AbbVie Inc. ($1,846) |
| 2019 | $66.44 | 1 | AstraZeneca Pharmaceuticals LP ($66.44) |
| 2018 | $98.79 | 1 | AstraZeneca Pharmaceuticals LP ($98.79) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $26.74 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $133.44 | General |
| 01/12/2022 | ABBVIE INC. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $337.50 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2021 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $45.97 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2021 | AbbVie Inc. | VENCLEXTA (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: ONCOLOGY | ||||||
| 05/12/2021 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $21.81 | General |
| Category: ONCOLOGY | ||||||
| 03/28/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $66.44 | General |
| Category: Oncology | ||||||
| 09/27/2018 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $98.79 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 974 | 2,284 | $557,834 | $159,502 |
| 2022 | 15 | 779 | 1,531 | $544,999 | $169,933 |
| 2021 | 6 | 221 | 312 | $122,023 | $39,299 |
All Medicare Procedures & Services
34 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 248 | 772 | $249,356 | $71,201 | 28.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 102 | 283 | $122,822 | $37,043 | 30.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 139 | 139 | $70,195 | $16,821 | 24.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $26,875 | $6,857 | 25.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 82 | 98 | $21,462 | $6,093 | 28.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 191 | 704 | $14,080 | $5,914 | 42.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 36 | 83 | $18,011 | $4,914 | 27.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 27 | 34 | $15,411 | $3,333 | 21.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 30 | $9,330 | $2,672 | 28.6% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 26 | 26 | $2,860 | $1,870 | 65.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 18 | 18 | $3,150 | $1,073 | 34.1% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Office | 2023 | 21 | 28 | $2,800 | $873.08 | 31.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 26 | 26 | $1,482 | $838.43 | 56.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 213 | 562 | $181,526 | $58,179 | 32.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 94 | 369 | $160,146 | $55,677 | 34.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 136 | 136 | $68,680 | $17,640 | 25.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 38 | 115 | $35,765 | $9,681 | 27.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 49 | 49 | $30,625 | $8,670 | 28.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 59 | 65 | $14,235 | $4,965 | 34.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 36 | 39 | $16,554 | $4,359 | 26.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 16 | 18 | $11,034 | $2,976 | 27.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 28 | 50 | $10,850 | $2,941 | 27.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 23 | 27 | $4,725 | $1,457 | 30.8% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 13 | 14 | $4,452 | $1,198 | 26.9% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 12 | 14 | $3,500 | $1,185 | 33.8% |
About Michael Schieber
Michael Schieber is a Hematology & Oncology healthcare provider based in Lake Forest, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/13/2015. The National Provider Identifier (NPI) number assigned to this provider is 1609267533.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Michael Schieber has received a total of $2,531 in payments from pharmaceutical and medical device companies, with $160.18 received in 2024. These payments were reported across 8 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($2,138).
As a Medicare-enrolled provider, Schieber has provided services to 1,974 Medicare beneficiaries, totaling 4,127 services with total Medicare billing of $368,734. Data is available for 3 years (2021–2023), covering 34 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Student in an Organized Health Care Education/Training Program
- Location Lake Forest, IL
- Active Since 02/13/2015
- Last Updated 08/26/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1609267533
Products in Payments
- VENCLEXTA (Drug) $2,210
- IMFINZI (Drug) $98.79
- TAGRISSO (Drug) $66.44
- KEYTRUDA (Biological) $21.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.